Table 2.
Comparison between baseline characteristics and clinico-pathological parameters of BC patients analysed by germline BRCA1/2 and multi-gene panel testing
| BRCA1/2 mut | Multi-gene panel mut | All wt | P valuea | P valueb | |
|---|---|---|---|---|---|
| Number of patients | 83 | 24 | 589 | — | — |
| Age at diagnosis (years) | |||||
| Median | 41 | 32 | 44 | ||
| Mean | 42.6 | 45.6 | 44.5 | ||
| Range | 28-80 | 27-71 | 21-84 | 0.32 | 0.24 |
| Age groups (years), n (%) | |||||
| ≤40 | 40 (48.2) | 9 (37.5) | 241 (40.9) | ||
| 41-50 | 26 (31.3) | 7 (29.2) | 194 (32.9) | ||
| 51-60 | 13 (15.7) | 5 (20.8) | 105 (17.9) | ||
| >60 | 4 (4.8) | 3 (12.5) | 49 (8.3) | 0.48 | 0.86 |
| Histological subtype, n (%) | |||||
| Ductal | 72 (86.8) | 13 (54.2) | 456 (77.4) | ||
| Lobular | 7 (8.4) | 2 (8.3) | 47 (8) | ||
| Others | 4 (4.8) | 2 (8.3) | 49 (8.3) | ||
| Unknown | — | 7 (29.2) | 37 (6.3) | <0.0001 | <0.0001 |
| Molecular subtype, n (%) | |||||
| Luminal | 46 (55.4) | 15 (62.5) | 397 (67.4) | ||
| HER2E | 3 (3.7) | 1 (4.2) | 33 (5.6) | ||
| TNBC | 34 (40.9) | 3 (12.5) | 149 (25.3) | ||
| Unknown | — | 5 (20.8) | 10 (1.7) | 0.0001 | <0.00001 |
| ER, n (%) | |||||
| ≤20 | 8 (9.7) | — | 19 (3.2) | ||
| >20 | 34 (40.9) | 16 (66.6) | 355 (60.3) | ||
| Negative | 37 (44.6) | 4 (16.7) | 165 (28) | ||
| Unknown | 4 (4.8) | 4 (16.7) | 50 (8.5) | 0.014 | 0.41 |
| PR, n (%) | |||||
| ≤20 | 19 (22.9) | 2 (8.4) | 76 (12.9) | ||
| >20 | 23 (27.7) | 12 (50) | 286 (48.6) | ||
| Negative | 37 (44.6) | 5 (20.8) | 165 (28) | ||
| Unknown | 4 (4.8) | 5 (20.8) | 62 (10.5) | 0.004 | 0.38 |
| Ki-67, n (%) | |||||
| <20 | 8 (9.7) | 5 (20.8) | 158 (26.9) | ||
| 20-50 | 31 (37.3) | 8 (33.3) | 211 (35.8) | ||
| >50 | 39 (47) | — | 134 (22.7) | ||
| Unknown | 5 (6) | 11 (45.9) | 86 (14.6) | <0.00001 | 0.0006 |
| Histological grade, n (%) | |||||
| G1 | 2 (2.4) | 2 (8.4) | 62 (10.5) | ||
| G2 | 18 (21.7) | 8 (33.3) | 212 (36) | ||
| G3 | 58 (69.9) | 3 (12.5) | 226 (38.4) | ||
| Unknown | 5 (6) | 11 (45.8) | 89 (15.1) | <0.00001 | 0.0005 |
| Tumour size (T), n (%) | |||||
| T1 | 38 (45.8) | 8 (33.3) | 261 (44.4) | ||
| T2 | 23 (27.7) | 4 (16.7) | 145 (24.6) | ||
| T3 | 3 (3.6) | — | 18 (3) | ||
| T4 | 2 (2.4) | — | 6 (1) | ||
| unknown | 17 (20.5) | 12 (50) | 159 (27) | 0.12 | 0.16 |
| Axillary nodal involvement (N), n (%) | |||||
| N0 | 30 (36.1) | 2 (8.3) | 257 (43.7) | ||
| N1 | 24 (28.9) | 6 (25) | 108 (18.3) | ||
| N2 | 8 (9.6) | 3 (12.5) | 23 (3.9) | ||
| N3 | 5 (6) | — | 9 (1.5) | ||
| unknown | 16 (19.4) | 13 (54.2) | 192 (32.6) | 0.009 | 0.005 |
| Bilateral, n (%) | |||||
| Yes | 19 (22.9) | 11 (45.8) | 121 (20.5) | ||
| No | 64 (77.1) | 13 (54.2) | 468 (79.5) | 0.04 | 0.008 |
| Median age at diagnosis (years) | |||||
| Primary tumour | 40 | 53 | 46 | ||
| Secondary tumour | 50 | 63 | 52 | 0.86 | 0.85 |
| Time between first and second tumours (years) | |||||
| Median | 8 | 7 | 3 |
ER, estrogen receptor; PR, progesterone receptor; mut, mutated; TNBC, triple-negative breast cancer; wt, wild type.
a
Comparison between BRCA1/2 mut versus multi-gene panel mut patients.
b
Comparison between multi-gene panel mut versus all wt patients.